Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 12Neoplasms by Site 1Neoplasms 1ESR1 Gene Mutation 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Diseases 1Brain Neoplasms 1Brain Diseases 1Advanced ER+, HER2-Negative Breast Cancer 1Advanced Breast Cancer 1

Interventions

Fulvestrant 13Letrozole 6Anastrozole 5palbociclib 4exemestane 3Injections 3Docetaxel 3Paclitaxel 2Goserelin 2Dasatinib 2Capecitabine 2Alpelisib 2AZD9833 2vandetanib 1ribociclib 1irinotecan sucrosofate 1entinostat 1elacestrant 1cediranib 1abemaciclib 1XMT-1522 1Vinorelbine 1Sirolimus 1Ritonavir 1Lead 1Itraconazole 1Immunotherapy, Adoptive 1Everolimus 1Decitabine 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Breast Cancer × elacestrant × Clear all
NCT06638307 2026-05-12

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Stemline Therapeutics, Inc.

Phase 1 Recruiting
240 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡